跳至主要内容
临床试验/NCT06666101
NCT06666101尚未招募不适用

Immunomodulatory Effects of Polyunsaturated ω-3 Fatty Acids in Old Patients With Polyvascular Disease: a Double-blind, Randomized, Controlled, Factorial 2x2 Trial ("OMEGA3" Study)

Université Libre de Bruxelles0 个研究点目标入组 80 人开始时间: 2024年11月4日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
80
主要终点
Attenuation of production of inflammatory mediators

研究概览

简要总结

The objectives is to evaluate the effect of omega-3 fatty acids in old participants with polyvascular disease on immune parameters and inflammatory mediators at different times. Three modalities of administration of omega-3 will be compared with a placebo (olive oil): predominant EPA (Eicosapentaenoic acid), predominant DHA (doxosahexaenoic acid), and combinaison of both. This study will measure the level of omega3 fatty acids in this population 4 hours after taking, on the 7th day, on the 21th day of administration and 1 month after administration.

详细描述

Medical Background

Declines in immune function with age and an imbalance between pro- and anti-inflammatory mechanisms lead to a high incidence of infectious and cardiovascular disease among older individuals. ω-3 polyunsaturated fatty acids (EPA and DHA) are anti-inflammatory and represent a substrate of potent mediators, termed specialized proresolving mediators (SPMs). Specialized proresolving mediators (SPMs) are known to limit excessive neutrophil and monocyte migration and stimulate the uptake of apoptotic neutrophils and microbes, thus promoting the resolution of inflammation. Increases in SPM concentrations are linked with decreased uptake of oxidized low-density lipoproteins . Phagocyte functional decline with senescence has been well established. Aged macrophages exhibit functional changes such as compromised chemotaxis, impaired ability to phagocytose pathogenic bacteria, reduced expression of MHC class II molecules and decreased capacity for antigen presentation. However, how phagocyte dysfunction changes with the acquisition of a senescence phenotype is currently unknown.

Some components, such as polyunsaturated fatty acids (n-3 PUFAs), also prevent the induction of senescence and atherosclerosis but also have extensive immunomodulatory effects. The supplementation of fish oil (4 g n-3 PUFA/d) for 3 weeks in healthy older subjects induced dynamic reshaping of human CD4+ T cells and plasma membrane organization. Additionally, 5 days of n-3 PUFA supplementation was associated with an increase in the phagocytic activity of peripheral blood monocytes and neutrophils. The utility of n-3 PUFA-enriched supplements in the prevention of cardiovascular disease has been highlighted. Recently, the EVAPORATE study revealed that the combination of icosapentethyl, a highly purified form of eicopentaenoic acid ethyl ester, and statins might increase the regression of low-attenuation plaque volume on multidetector computed tomography compared with a placebo over 18 months. Specialized proresolving mediators (SPMs), bioactive lipids derived from n-3 PUFAs and leading to the resolution of inflammation, seem to be potential biomarkers for determining the immune regulatory potential of n-3 PUFAs. While native and mox LDL induce the release of inflammatory cytokines and mediators derived from docosahexaenoic acid (DHA) resolvin D1 from young endothelial cells, the effect of mox-LDL in senescent cells on SPM production is unknown. Eicosapentaenoic acid (EPA) and DHA significantly reduce H2O2-induced senescence-associated β-galactosidase activity in cells (by 31% and 22%, respectively). The consumption of fish oil, the main source of n-3 PUFAs, increases phagocytosis and the population of CD4+ and CD8+ lymphocytes in forty-five older healthy Caucasian women.

Drug profile

The substances evaluated will be polyunsaturated fatty acids such as eicosapentaenoic acid (EPA or C20: 5ω-3) and docosahexaenoic acid (DHA or C22: 6 ω-3).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
75 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 75 years old
  • Patients with polyvascular disease in cases of vascular lesions in ≥2 disease territories or any combination of coronary, peripheral, or carotid artery disease.
  • Able to comply with the requirements of the study protocol
  • Signed informed consent form approved by the ethical committee
  • No illness or event within 2 months prior to inclusion (hospitalization, trauma, active cancer, infection, acute failure of chronic disease, surgical intervention)
  • No history of multiple and/or severe allergies to drugs or foods
  • No consumption of fish oil or omega-3 fatty acid supplements within 2 months prior to inclusion
  • No consumption of more than 500 mg/day of dietary omega-3 fatty acids (questionnaire)
  • No intake of anti-inflammatory or corticosteroid medication within 2 weeks prior to inclusion
  • Able and authorized to take a pill
  • No intervention planned in the months following the start of the study

排除标准

  • Inflammatory syndrome (CRP >10 mg/l) on day 0 and day 7
  • Acute illness or event during the time of intervention

结局指标

主要结局

Attenuation of production of inflammatory mediators

时间窗: Day 0, Day 21

lowering plasma IL8 in pg/ml

次要结局

  • Enhanced production of proresolving mediators(Day 0, Day 21)
  • Increased level of EPA and DHA(Day 0, 4 hours post dose , Day 7, Day 21, Day 56)
  • Attenuation of production of senescence-associated secretory phenotype(Day 0, Day 21)
  • Attenuation of production of inflammatory mediators from immune cells(Day 0, Day 21)
  • Improving immune parameters(Day 0, Day 7, Day 21, Day 51)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Korpak Kéziah

Korpak Kéziah, medical doctor

Université Libre de Bruxelles

相似试验

Effects of n3 LC PUFAs on Inflammatory, Immune and... | 临床试验